Study of Combination Ruxolitinib and Decitabine Treatment for Accelerated Phase MPN or Post-MPN AML

• ClinicalTrials.gov Identifier: NCT02076191
• Recruitment Status: Completed
• First Posted: March 3, 2014
• Last Update Posted: February 28, 2019
• Sponsor: John Mascarenhas
• Collaborators: Myeloproliferative Disorders-Research Consortium; National Cancer Institute (NCI); Incyte Corporation
• Information provided by (Responsible Party): John Mascarenhas, Icahn School of Medicine at Mount Sinai

Results Submitted - Not Posted on ClinicalTrials.gov

Results information has been submitted to ClinicalTrials.gov by the sponsor or investigator, but is not yet publicly available (or "posted") on ClinicalTrials.gov. The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.

• Recruitment Status: Completed
• Actual Primary Completion Date: July 20, 2018
• Actual Study Completion Date: July 20, 2018

Submission Cycle	Results Submitted to ClinicalTrials.gov	Results Returned after Quality Control Review
1	December 11, 2019	December 26, 2019

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Mascarenhas JO, Rampal RK, Kosiorek HE, Bhave R, Hexner E, Wang ES, Gerds A, Abboud CN, Kremyanskaya M, Berenzon D, Odenike O, Farnoud N, Krishnan A, Weinberg RS, McGovern E, Salama ME, Najfeld V, Medina-Martinez JS, Arango Ossa JE, Levine MF, Zhou Y, Sandy L, Heaney ML, Levine RL, Mesa RA, Dueck AC, Hoffman R. Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase. Blood Adv. 2020 Oct 27;4(20):5246-5256. doi: 10.1182/bloodadvances.2020002119.